Semax: the complete research guide.

Semax is a synthetic seven-amino-acid fragment of ACTH, approved in Russia for stroke recovery and approved nowhere in the West. We read 13 published studies on it: stroke transcriptomics, BDNF and NGF effects, fMRI imaging, and independent Italian replication of the copper-binding work.

If you set out to design the most-credentialed grey-market peptide possible, you'd end up with something close to Semax. The molecule is a structural analog of a known hormone fragment, ACTH 4–7. Russia has approved it for over 20 years for a serious indication: acute ischemic stroke.

It also has the most active and most consistent Russian research program of any peptide we cover. And independent non-Russian academic groups have replicated key mechanistic findings, with no authorship overlap.

That last point matters. The usual critique of Russian-school peptides is that the literature sits with one group and nobody outside replicates it. BPC-157 has the same problem from its Zagreb lab.

Semax has actually been replicated. Italian groups confirmed its copper-binding and amyloid-β effects. That doesn't validate the full Russian clinical claim. It does show some of the mechanism survives when other labs run the experiments.

And yet: no Western Phase III, no PubMed-indexed Western RCT in any indication, no FDA or EMA approval. The same evidentiary wall as Selank. Here's what the published Western literature actually documents.

What is Semax, structurally?

Semax is a 7-residue peptide. The sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first 4 residues match a section of ACTH, or adrenocorticotropic hormone. That's the 4–7 fragment, which is neuro-active on its own. The C-terminal Pro-Gly-Pro tail is the same trick used in Selank. It makes the molecule resistant to enzymatic breakdown, while keeping the active core's behavior intact.

Here's the structural twist that matters. Semax is described as "non-corticotropic". Despite its ACTH lineage, it doesn't release cortisol the way full-length ACTH does. The 4–7 sequence carries the brain-active part of ACTH without the steroid-releasing part. That's the basis for the "neuroactive without HPA-axis activation" pitch that the Russian clinical use rests on.

The development team is the same group that made Selank: Myasoedov and Andreeva, at what's now the Kurchatov Institute. The two molecules are commercial and academic siblings, designed by the same Russian research complex. Their evidentiary structure is parallel. Selank is the anxiety drug. Semax is the stroke-recovery drug.

What does Semax actually do?

The mechanism picture for Semax is unusually well-developed for a Russian-school peptide. The Kurchatov Institute group has published a run of studies over the past 5 years mapping the molecule at three levels: gene expression, protein expression, and behavior.

The documented effects include BDNF and NGF upregulation, plus anti-inflammatory cytokine changes in stroke models. Add modulation of CREB, MMP-9, c-Fos and JNK signaling, allosteric GABA receptor effects, copper binding, and dopamine and serotonin changes.

BDNF and NGF are the two best-studied growth factors for nerve cells. That's brain-derived neurotrophic factor and nerve growth factor. Both are central to learning and memory. Compounds that raise their levels have been the focus of cognition research for decades. Semax raises both in rodents. That's the proposed substrate for its cognitive effects.

The Kurchatov stroke transcriptomics work is the deepest single part of the evidence base. Filippenkov and colleagues published a 2024 study showing Semax restored normal expression of 1,171 genes that ischemia had disrupted. They measured 24 hours after a rat stroke model, using transient middle cerebral artery occlusion.

Sudarkina's 2021 paper documented Semax's effects on four key proteins at that same 24-hour point: CREB, MMP-9, c-Fos and JNK. Filippenkov's 2023 paper added immune-gene data from the early post-stroke window.

Dergunova's Russian-language 2021 paper showed Semax suppresses the pro-inflammatory signals stroke triggers, including IL-1α, IL-1β, IL-6, CCL3 and CXCL2.

We'd call that unusually rigorous preclinical work. Multi-time-point RNA-seq in a standardized stroke model, with consistent methods across papers, isn't what a typical "research peptide" evidence base looks like.

Semax

ACTH(4-10) analog 7 aa N-acetylated

The same compound cited across the 13 studies in this review. Lab-verified identity and purity.

Shop Semax

What does independent replication look like?

The Italian copper work is the most important non-Russian piece of the Semax evidence base. Sciacca and colleagues at the University of Catania published a 2022 study showing Semax binds copper ions, Cu²⁺.

Semax also blocks Cu²⁺-Aβ complexes from forming, cuts copper-driven reactive oxygen species, and protects neuroblastoma cells from oxidative stress. Tomasello and colleagues, from the same Italian environment, extended the finding in 2025.

Copper imbalance is one of several proposed contributors to Alzheimer's disease pathology. It interacts with amyloid-β aggregation and with oxidative stress. A compound that binds Cu²⁺, prevents Cu-Aβ complexes and lowers oxidative stress has a plausible mechanistic link to Alzheimer's. Not as a treatment. As a research tool with a defined biochemical effect.

For our purposes, who did this work is what matters. The Italian group shares no authors with the Russian developers. They sit in a Western academic institution, and their methods are published for anyone to check.

An overlapping but distinct Italian team repeated the finding in a 2025 follow-up. That's exactly the corroboration the wider Russian-school peptide literature usually lacks.

What does the 2020 fMRI study show?

The same 2020 Panikratova study that gives Selank its best Western human evidence also covered Semax. The placebo-controlled three-way design set Selank against Semax against placebo, in 52 healthy adults. Brain scans were taken before dosing, 5 minutes after, and 20 minutes after, as Panikratova and colleagues reported in 2020.

For Semax specifically, the team documented changes in the right amygdala's connectivity to several right temporal cortical regions: fusiform, inferior temporal, middle temporal and parahippocampal gyri. That's broadly the same fear-and-emotion network Selank engages, with some quantitative differences.

The interpretation is the same. You get real, measurable CNS engagement in humans within a short window. You don't get proof of clinical efficacy in patients with stroke or cognitive impairment.

As a healthy-volunteer biomarker study, the methodology is solid: placebo control, three arms, repeated measures, MRI. As a stand-in for a Phase III efficacy trial, it falls well short. Both things can be true.

What about the other preclinical findings?

Beyond the stroke transcriptomics and the Italian copper work, we found a handful of other Semax results worth your time.

Spinal cord injury, 2025. Liu and colleagues published in the British Journal of Pharmacology that Semax improved recovery in a mouse spinal cord injury model. It suppressed pyroptosis, a pro-death cell-signaling pathway, through μ-opioid receptor engagement. That's a novel mechanism implicating the opioid system, in a major peer-reviewed pharmacology journal.

Antidepressant-like effects, 2024. Inozemtseva and the Kurchatov team showed Semax at 60 nmol/kg/day reversed depression-like changes in chronically stressed rats: anhedonia, body weight loss, adrenal gland enlargement, and dropped hippocampal BDNF.

Neonatal SSRI exposure, 2020. Glazova and colleagues reported that Semax given to rats neonatally exposed to an SSRI reduced anxiety behaviors, improved learning, and normalized brain amine levels.

Diabetes lipid effects, 2020. Elagina and colleagues documented Semax at 200 mcg/kg correcting lipid metabolism problems in a rat diabetes model. It reduced total cholesterol, triglycerides, LDL, and atherogenicity. It raised HDL.

Restraint stress and the gut, 2021. Svishcheva and colleagues showed Semax at 5–450 mcg/kg reduced corticosterone, eased stress-driven colon damage, and helped rats adapt under restraint. The pattern parallels the Selank gut-protection data.

GABA receptor modulation, 2023. Vyunova and colleagues characterized Semax's direct and delayed effects on the GABA receptor system, adding mechanism detail to its anxiety-adjacent activity.

Does delivery route matter? (Nasal vs subcutaneous)

Semax is approved in Russia as a nasal spray. Intranasal delivery is the primary route in Russian clinical practice and in Russian preclinical work alike.

The nasal route has two practical advantages. It bypasses first-pass metabolism. And some of the dose reaches the brain directly along the olfactory tract and trigeminal nerve, sidestepping the blood-brain barrier that stops most peptide drugs.

Western grey-market use is mostly subcutaneous injection. That's the standard route for research peptides. The injection route presumably produces a different drug behavior in the body: higher peak blood levels, lower direct brain delivery, longer half-life from slower absorption. Whether subcutaneous Semax produces the same effects as intranasal Semax is unanswered by any published study.

The practical implication for researchers is simple. Subcutaneous dosing is the most common route in Western work, and the Russian trials behind the approval never validated it. The mechanism is the same. The pharmacokinetics are not.

Why isn't there a Western RCT?

Our answer is the same one we gave for Selank, with one twist. Russian institutions hold the intellectual property, and no Western sponsor has a commercial incentive.

Stroke neuroprotection is dominated by tPA and thrombectomy, leaving little room for an add-on peptide. Phase III failure rates in CNS drug development would deter a sponsor anyway.

A second factor is which research context Semax has actually been studied in. The largest body of mechanistic work covers ischemic stroke and specific cognitive-deficit models. Work in neurologically intact adults stops at the 2020 Panikratova fMRI study.

The mechanistic work on BDNF, NGF, copper chelation and stroke gene expression is substantial. None of it is validated efficacy data for cognition endpoints in healthy people.

Semax

11 mg ≥99% pure Lyophilized

ACTH(4-10) analog · 7 aa, N-acetylated. The same reference compound used across the cited preclinical studies. COA available with each lot.

Learn more

What about side effects?

Published Russian clinical literature describes Semax as well-tolerated at the nasal-spray doses used in its approved short-course indications. The most commonly noted issue is mild nasal irritation. Systemic adverse events are described as uncommon.

Because Semax is "non-corticotropic," it doesn't trigger cortisol release despite its ACTH lineage. No published study documents HPA-axis activation.

The gaps in the safety evidence are notable. Russian approval covers short-course use, days to weeks, in stroke or specific cognitive-deficit contexts. Long-term safety data are essentially absent from the published literature.

Interactions with neuroactive agents look plausible given Semax's broad receptor-level effects. That includes SSRIs, opioids and GABA-active compounds. No formal pharmacokinetic interaction study has been published.

The 2025 Liu finding that Semax engages the μ-opioid receptor raises a specific open question about co-administration with opioids. Nobody has investigated it yet.

Open research questions

Several questions stay unresolved in the published literature. For cognitive endpoints in neurologically intact people, we'd call the mechanistic evidence suggestive and the clinical efficacy unestablished. For post-stroke recovery and specific deficit contexts, Russian clinical experience exists but nobody has replicated it to Western Phase III standards.

• Kurchatov transcriptomics: multi-time-point RNA-seq data in a standardized stroke model represents the deepest mechanistic work published for any Russian-school peptide.
• Delivery route equivalence: the validated Russian route is intranasal. Subcutaneous administration, used in most Western preclinical protocols, has not been compared head-to-head with intranasal in a published pharmacokinetic study.
• Interaction studies: the μ-opioid receptor engagement documented by Liu et al. (2025) raises a specific open question for co-administration protocols with opioid compounds — not yet characterized in a published interaction study.
• Independent replication: the Italian copper / Aβ work and the Liu et al. spinal cord injury finding represent the most credible non-Russian replications; further independent replication of the full Kurchatov stroke transcriptome claims would strengthen the evidentiary base.
• Western RCT: no PubMed-indexed Phase II or Phase III trial has been registered or published for any Western indication as of 2026.